Golidocitinib for Mycosis Fungoides/Sezary Syndrome and Large Granular Lymphocytic Leukemia

(GEMSTONE Trial)

This trial tests a new treatment called golidocitinib for two rare blood conditions: mycosis fungoides/Sézary syndrome (a type of skin lymphoma) and T-cell large granular lymphocytic leukemia (a disorder affecting certain white blood cells). The goal is to determine if a daily pill of golidocitinib benefits people with these conditions, particularly those who have tried other treatments. Suitable participants have one of these conditions, require further treatment, and can take medication in pill form. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Research has shown that golidocitinib is generally well-tolerated by patients with certain types of lymphoma. In one study with 104 patients, about 59% experienced serious side effects, classified as grade 3-4, indicating significant severity. However, for some patients, the benefits of the drug might outweigh the risks.

Another study found that golidocitinib produced promising results and was safe for patients who had already tried many other treatments, meaning many of these patients did not experience severe problems with golidocitinib.

Researchers are excited about golidocitinib because it offers a novel approach compared to existing treatments for mycosis fungoides/Sézary syndrome and large granular lymphocytic leukemia. Unlike current options that often include chemotherapy and immunotherapy, golidocitinib is a daily oral pill, which can make it more convenient and less invasive for patients. Additionally, golidocitinib targets specific pathways involved in the disease process, potentially leading to more effective and targeted treatment outcomes. This unique action could provide new hope for patients who have exhausted other treatment options.

Research has shown that golidocitinib yields promising results for treating conditions like mycosis fungoides and Sézary syndrome. In previous studies, golidocitinib reduced tumor size, with 44% of patients with relapsed or hard-to-treat peripheral T-cell lymphoma responding to the treatment. This trial includes a cohort for patients with advanced-stage mycosis fungoides/Sézary syndrome who will receive golidocitinib. In another cohort for large granular lymphocytic leukemia, golidocitinib quickly improved blood counts in many patients, although more research is needed to understand the long-term effects. Overall, early findings suggest that golidocitinib might effectively manage these types of cancers.⁶⁷⁸⁹¹⁰